Clinical trials
RSV clinical trials
Below are recruiting rsv clinical trials, each written for real people, not researchers. We’re tracking 58 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07239583Recruiting
RSV infection and health impact in older adults in Vietnam
This study looks at how common RSV (a virus that can cause serious breathing problems) is in older adults who are hospitalized with respiratory symptoms or worsening heart/lung conditions. By joining, you help researchers understand the virus and improve care for people your age.
Ho Chi Minh City, Southern VietnamAges 60 years+ - NCT07214571RecruitingPhase 2
Study of S-337395 for RSV in high-risk adults
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
Los Angeles, CaliforniaAges 18 years+ - NCT06775405RecruitingPhase 3
Testing a new RSV treatment for hospitalized babies
This study tests a medicine called AK0529 for babies and toddlers hospitalized with RSV. It aims to see if the drug helps them recover faster and is safe for this age group.
BeijingAges 1 month–2 years - NCT06511687Recruiting
Nirsevimab effectiveness for RSV in Chilean infants
This study tests if the medicine Nirsevimab can help prevent severe RSV (a common winter virus) in infants in Chile. It is for babies born at specific times in 2023–2024, especially those born early or with health problems.
SantiagoAges Up to 4 years - NCT07640581Recruiting
RSV Infection Study in Babies Under 2 Years
This study tracks how respiratory syncytial virus (RSV)—a common respiratory infection in babies—affects children under 24 months in Ho Chi Minh City. Researchers want to understand how often RSV happens, how severe it is, and how it impacts families, so they can better prepare healthcare services.
Ho Chi Minh City, Ho Chi MinhAges birth–2 years - NCT06881056Recruiting
Aerosol interferon for RSV pneumonia in toddlers
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
Chengdu, SichuanAges 1–3 - NCT07106918RecruitingEarly Phase 1
SIBP-A16 Injection Safety Study in Healthy Adults
This study tests an experimental injection called SIBP-A16 in healthy adults to see if it is safe and how the body handles it. It helps researchers learn about the drug before testing it in people with a medical condition.
WuhanAges 18–45 - NCT07653100RecruitingPhase 3
RSV vaccine study for adults with chronic conditions
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
Visakhapatnam, Andhra PradeshAges 18 years+ - NCT06488300RecruitingPhase 2
Testing antiviral treatments for early RSV
This trial tests if antiviral medications can help adults with early respiratory syncytial virus (RSV) feel better faster. It is for people aged 18 to 64 who have had RSV symptoms for 4 days or less and have tested positive for the virus.
VientianeAges 18–64 - NCT07601412Recruiting
Understanding Immune Response to Respiratory Viruses in Older Adults
This study examines how the body's natural defense system (specifically a type of immune protein) responds to common respiratory viruses like flu and cold in older adults. Researchers will analyze nasal samples that are already being collected as part of routine care to better understand why older people sometimes have different immune responses to these infections.
LyonAges 60 years+ - NCT07272434RecruitingPhase 3
RSV vaccine trial for adults 60 and older
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
Guangzhou, GuangdongAges 60 years+ - NCT07050732RecruitingPhase 2
Testing RSV vaccine in people with weakened immune systems
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
Baltimore, MarylandAges 18 years+ - NCT06856967Recruiting
Nirsevimab for RSV in infants under 1 year
This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.
Arezzo, ArezzoAges Up to 1 year - NCT07653347Recruiting
Infant RSV immunity study
Researchers want to study how infants naturally fight RSV infections. You and your baby may join if your baby is born in April, May, June, September, October, or November at BC Women's Hospital or a nearby hospital.
Vancouver, British ColumbiaAges Up to 6 months - NCT07030075Recruiting
Flu and respiratory infection study in Lusaka
This study looks at flu-like symptoms and other respiratory infections in adults in Lusaka, Zambia. It aims to understand how these infections affect people with and without HIV, and may help improve care.
Lusaka, Lusaka ProvinceAges 18 years+ - NCT06665100RecruitingPhase 2
Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT07599449Recruiting
Tracking respiratory infections in French primary care
This study tracks viruses that cause sudden colds and flu-like illnesses during winter months in France. Researchers collect information from patients seen by participating doctors to better understand which respiratory viruses are circulating and help prepare for future outbreaks.
ParisAges Any age - NCT04959734Recruiting
Study of COVID-19 effects on emergency visits for infant lung infections
This study looks at how the COVID-19 era changed emergency department visits for young children with breathing problems, such as bronchiolitis or first-time viral wheeze. It may help doctors understand trends in these illnesses and plan better care during outbreaks.
LeicesterAges birth–2 years - NCT05045612RecruitingPhase 4
Antibiotics for certain viral lung infections in hospitalized adults
This trial studies whether giving antibiotics affects recovery in adults hospitalized with moderately severe infections caused by specific viruses (influenza, parainfluenza, RSV, or hMPV). It may help show when antibiotics are helpful or unnecessary for viral airway illness.
BergenAges 18 years+ - NCT06160128Recruiting
VA study on COVID-19 and medication effectiveness
This study looks at how well COVID-19 treatments work for veterans. It uses VA health records to see what medicines help and how people recover. You may be able to join if you are a veteran in VA care.
Portland, OregonAges 18 years+ - NCT06180993Recruiting
Nirsevimab for infants born in Galicia
This trial tests a preventive medicine called nirsevimab given to infants to see how well it protects them from a common serious lung infection. It is offered as part of regular check-ups for babies born during a specific time period.
Santiago de Compostela, A CoruñaAges 1 day–2 years - NCT06197152Recruiting
RSV severity markers in hospitalized adults
This study looks for markers in the blood that can tell how serious an RSV infection might become. If you are hospitalized with RSV and have breathing symptoms, this trial will follow your recovery and test for clues about your illness.
CréteilAges 18 years+ - NCT06684379RecruitingPhase 1/Phase 2
Two Doses of PRS CK STORM for Severe Viral Pneumonia
This study tests a new drug called PRS CK STORM to see if it can safely calm the body's overactive immune response (cytokine storm) in people with severe pneumonia from COVID-19, flu, or RSV who need oxygen. It aims to reduce inflammation and improve recovery.
Alcalá de Henares, MadridAges 18 years+ - NCT06817889RecruitingPhase 2
Remdesivir for RSV in people with weak immune systems
This trial tests if remdesivir can safely treat RSV (a respiratory virus) in people with weakened immune systems, such as those who have had a stem cell or bone marrow transplant, CAR T-cell therapy, or are being treated for blood cancer. If you have a confirmed RSV infection in your nose or throat and are at moderate or high risk for complications, you may be able to join.
Duarte, CaliforniaAges 18 years+
Hear when a new RSV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rsv?
- Yes. Clin2 currently lists 58 recruiting rsv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rsv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rsv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.